Nicole Sweeny Sells 1,489 Shares of KalVista Pharmaceuticals (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,489 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total transaction of $39,875.42. Following the sale, the insider owned 59,291 shares of the company’s stock, valued at approximately $1,587,812.98. The trade was a 2.45% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Friday, May 22nd, Nicole Sweeny sold 1,861 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $26.78, for a total transaction of $49,837.58.
• On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock traded down $0.02 during trading hours on Wednesday, hitting $26.79. 2,466,702 shares of the company were exchanged, compared to its average volume of 2,436,684. The firm has a fifty day simple moving average of $21.74 and a 200 day simple moving average of $17.54. The company has a current ratio of 5.17, a quick ratio of 5.10 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a 52-week low of $9.83 and a 52-week high of $26.85. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings results on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. Research analysts predict that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KALV has been the subject of several research analyst reports. Wall Street Zen lowered shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Stifel Nicolaus raised their price objective on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. Needham & Company LLC downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Finally, HC Wainwright downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $37.00 to $27.00 in a report on Friday, May 1st. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Hold” and an average price target of $30.60.

Institutional Trading of KalVista Pharmaceuticals

A number of hedge funds have recently made changes to their positions in KALV. AQR Capital Management LLC bought a new stake in KalVista Pharmaceuticals in the first quarter worth $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of KalVista Pharmaceuticals by 13.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company’s stock valued at $281,000 after buying an additional 2,939 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company’s stock worth $3,923,000 after buying an additional 12,263 shares during the period. Creative Planning lifted its stake in shares of KalVista Pharmaceuticals by 20.0% in the 2nd quarter. Creative Planning now owns 33,380 shares of the specialty pharmaceutical company’s stock valued at $377,000 after acquiring an additional 5,573 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in shares of KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Rhumbline Advisers now owns 54,376 shares of the specialty pharmaceutical company’s stock valued at $615,000 after acquiring an additional 1,458 shares during the last quarter.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.